Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-04-12
1998-07-21
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514281, 546 45, A01N 4342, A61K 3144
Patent
active
057835837
ABSTRACT:
Methods whereby the narcotic antagonist 17-(cyclopropylmethyl)-4,5alpha-6-methylenemorphinan-3,14-diol,hydrochlori de salt and other narcotic antagonists are used for chemically precipitating a withdrawal response in human beings addicted to exogenous narcotics and who are currently using exogenous narcotics.
REFERENCES:
patent: 3896226 (1975-07-01), Fishman
patent: 4535157 (1985-08-01), Meltzer et al.
patent: 4987136 (1991-01-01), Kreek et al.
patent: 5272149 (1993-12-01), Stalling
DuPont Pharma, package insert fo Narcan (naloxone), Feb. 1995.
Partidge et al., "Pulmonary Edema Following Low-dose Naloxone Administration", Anesthesiology, vol. 65, No. 6, pp. 709-710, 1986.
DuPont Pharma, package insert for Revia (naltrexone) , pp. 1-2, Jan. 1995.
Taff, "Pulmonary Edema Following Naloxone Administration in a Patient Without Heart Disease", Anesthesiology, 59, 576-77, 1983.
San et al., "High Risk of Ultrashort Noinvasive Opiate Detoxification", Am. J. Psychiatry 152, p. 956, Jun. 1995.
Brewer, C., "Ultra-rapid, antagonist-precipitated opiate detoxification under general anaesthesia or sedation", Addiction Biology 2/3, pp. 291-302, 1997.
Gerra et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction", Journal of Substance Abuse Treatment, vol. 12, No. 1, pp. 35-41, 1995.
Loimer et al., "Continuous Naloxone Administration Suppresses Opiate Withdrawal Symptoms In Human Opiate Addicts During Detoxification Treatment", 1989 pp. 81-86.
Text--Opioid Peptides in Substance Abuse by Jozsef I. Szekely, CRC Press, Inc., p. 160 (1994).
Article--Spanagel et al.--"Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway" Proc. Natl. Acad. Sci. USA vol. 89, p. 2046, Mar. 1992.
Article--Pan et al. "Cellular mechanism for anti-analgesic action of agonists of the k-opioid receptor" Naturevol. 389/25 Sep., pp. 382-385 (1997).
Article--Kreeks et al. "Orally Administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig" Life Sciences, vol. 56, No. 14, pp. 1187-1192, 1995.
Article--Arts et al. "Inhibition of the Antianalgesic Action of Dynorphin A in Mice by Cholera Toxin" Pharmacology Biochemistry and Behavior, vol. 46, pp. 623-629, 1993.
Article--Bakashi et al. "Dynorphin A-(1-17) Induces Alterations in Free Fatty Acids, Excitatory Amino Acids, and Motor Function Through An Opiate-Receptor-Mediated Mechanism" The Journal of Neuroscience, Dec. 1990, 10(12): 3793-3800.
Article--Behrmann et al. "A Comparison of YM-14673, U-50488H, and Nalmefene after Spinal Cord Injury in the Rat" Experimental Neurology 119, 258-267 (1993).
Article--Ohnishi et al. "Aquaretic Effect of the Stable Dynorphin-A analog E2078 in the Human" The Journal of Pharmacology and Experimental Therapeutics vol. 270, No. 1, Mar. 19, 1994. !-Dynorphin-A-(1-8)Ethylamide, a Stable Dynorphin Analog, Produces Diuresis by Kappa-Opiate Receptor Activation in the Rat" The Journal of Pharmacology and Experimental Therapeutics vol. 262, No. 3, 1992.
Article--Wang et al. "Contribution of Alpha-2 Adrenoceptors to Kappa Opioid Agonist-Induced Water Diuresis in the Rat" The Journal of Pharmacology and Experimental therapeutics vol. 270, 1994.
Article--O'Connor et al. Rapid and Ultrarapid Opioid Detoxification Techniques JAMA, Jan. 21, 1998--vol. 279, No. 3.
Jones Dwayne C.
Jordan Kimberly
LandOfFree
17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14- does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14- will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1647331